drugset / Trial / NCT04563208
Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a single center, randomized, double-blind, 2-arm, parallel-group study of DuACT in participants with clinical symptoms of COVID-19 that have begun within the past 72 hours prior to testing.
Timeline
- Start
- 2020-12-09
- Primary completion
- 2022-02-28
- Completion
- 2022-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Nitazoxanide | Other / unclassified | 500 mg | Oral |
| Comparator | Ribavirin | Small molecule | 400 mg | Oral |